- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Geriatrics
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Oncology
- Nephrology
- Neurology
- Pulmonology
Lebrikizumab Maintains Deep Response, QoL Through 3 Years in Atopic Dermatitis Extension Study
RAD 2025: Under lebrikizumab maintenance treatment in week 16 responders, approximately 8 out of 10 achieved almost clear skin up to 3 years.
Linda Stein Gold, MD
Photo courtesy of Henry Ford Health
Long-term treatment with lebrikizumab maintained and, in some cases, improved clinical response and patient-reported outcomes through 152 weeks in individuals with moderate-to-severe atopic dermatitis (AD), according to data from the ADjoin extension study presented at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville.
The study evaluated people who had achieved clinical response (IGA 0/1 or EASI 75) at week 16 in the phase 3 ADvocate1 and ADvocate2 trials and were subsequently enrolled into the long-term extension study, ADjoin. Responders were randomized to receive lebrikizumab 250 mg every 2 weeks (Q2W) or every 4 weeks (Q4W) through 152 weeks.
Among week 16 responders, approximately 80% maintained a deep clinical response, defined as EASI 90, through week 152. Additionally, more than 50% of participants achieved complete skin clearance, assessed by either EASI 100 or IGA 0. These results were consistent across both dosing regimens.
Notably, most participants (across both Q2W and Q4W arms) did not require rescue therapy, including topical corticosteroids (TCS), topical calcineurin inhibitors (TCIs), or systemic therapies, during the 3-year treatment period. Rescue medication use was permitted in the long-term extension phase on a case-by-case basis.
Improvement in health-related quality of life was also sustained. Approximately one-third of participants reported minimal to no AD-specific symptoms at week 152, as measured by the Patient-Oriented Eczema Measure (POEM) with scores of 0 or 1. POEM is a validated 7-item scale assessing the frequency of symptoms such as itch, sleep disturbance, and skin damage over the prior week, with lower scores indicating better symptom control.
The ADjoin study enrolled individuals aged ≥12 years who had completed ADvocate1 or ADvocate2 and had achieved clinical response at week 16 without requiring rescue therapy during the induction period. Baseline demographics were balanced between groups: the mean age was approximately 36 years, with a mean disease duration of over 22 years. About 14% of participants were adolescents.
At baseline in the parent studies, mean EASI scores were 28.9 (Q4W) and 29.2 (Q2W), and mean POEM scores were 20.1 and 21.0, respectively. Approximately 36% to 39% of participants had IGA scores of 4 (severe AD).
"These 3-year data suggest that long-term maintenance of total skin clearance is an achievable treatment goal for at least half of lebrikizumab Week 16 monotherapy responders," study authors concluded. Furthermore, the minimal need for rescue therapy and sustained quality-of-life improvements highlight the potential of lebrikizumab to provide durable disease control in chronic AD management.
The ADjoin study is part of the broader OASIS clinical development program sponsored by Eli Lilly and Company.
